Neuralstem (CUR) Receives FDA Approval to Commence First ALS Stem Cell Trial

September 21, 2009 8:21 AM EDT Send to a Friend
Neuralstem, Inc. (NYSE: CUR) announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login